dc.contributor.author | Abuga, K. | |
dc.contributor.author | Ndwigah, S. | |
dc.contributor.author | Amugune, B | |
dc.contributor.author | [et.al] | |
dc.date.accessioned | 2021-06-09T10:40:26Z | |
dc.date.available | 2021-06-09T10:40:26Z | |
dc.date.issued | 2021-04-12 | |
dc.identifier.citation | Abuga, K., Ndwigah, S., Amugune, B., Ongarora, D., Njogu, P., Okaru, A., & Kibwage, I. (2021). Quality Control Report of Drugs Analyzed in the Drug Analysis and Research Unit during the Period 2011-2015. The East and Central African Journal of Pharmaceutical Sciences, 23(3), 79-86 | en_US |
dc.identifier.uri | http://uonjournals.uonbi.ac.ke/ojs/index.php/ecajps/article/view/714 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke/handle/11295/155003 | |
dc.description.abstract | During the period 2011-2015, the Drug Analysis and Research Unit (DARU) analyzed
1972 drug samples. The samples consisted of 21.5% locally manufactured and 78.2%
imported products while the origin of 0.3% of products was indeterminate. Samples were
subjected to compendial and/or in-house analytical specifications. The overall noncompliance rate was 4.5% comprising 2.5% local products and 2.0% imports. High
failure rates were recorded for uterotonics (37.5%), hemostatics (33%), anthelmintics
(17%) and anticancers (10.5%) while ophthalmic, immunomodulatory, musculoskeletal
and endocrine drugs all complied with the quality acceptance criteria. Erectile
dysfunction drugs, received by the laboratory for the first time, all complied with
specifications. The results obtained demonstrate an improvement in the quality of
samples submitted to DARU when compared to previous performance. | en_US |
dc.language.iso | en | en_US |
dc.publisher | East and Central African Journal of Pharmaceutical Sciences | en_US |
dc.subject | DARU, drug analysis, drug class, pharmacovigilance, post-market surveillance | en_US |
dc.title | Quality control report of drugs analyzed in the drug analysis and research unit during the period 2011-2015 | en_US |
dc.type | Article | en_US |